• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

140.22 -3.45 (-2.40%)
Official Closing Price Updated: 7:00 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Glaukos Receives FDA 510(k) Clearance For iStent infinite ↗
August 03, 2022
The U.S. 
Via Benzinga
News headline image
Glaukos Announces FDA 510(k) Clearance of iStent infinite®
August 03, 2022
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Corporation Announces Second Quarter 2022 Financial Results
August 03, 2022
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3
July 13, 2022
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos: Q4 Earnings Insights ↗
February 22, 2022
Glaukos (NYSE:GKOS) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Glaukos... 
Via Benzinga
News headline image
Earnings Scheduled For February 22, 2022 ↗
February 22, 2022
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu... 
Via Benzinga
News headline image
Analyst Ratings For Glaukos ↗
January 19, 2022
Glaukos (NYSE:GKOS) has observed the following analyst ratings within the las... 
Via Benzinga
News headline image
The 6 Most Aggressive Growth Stocks to Buy in July ↗
July 12, 2022
These are the 6 most aggressive growth stocks to buy in July. They reflect huge potential growth in their sales and/or their earnings. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022 ↗
July 12, 2022
Upgrades 
Via Benzinga
News headline image
Glaukos Announces Participation in the William Blair Growth Stock Conference
June 02, 2022
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium
May 20, 2022
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Corporation Announces First Quarter 2022 Financial Results
May 04, 2022
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
April 21, 2022
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces the Release of its 2021 Sustainability Report
April 20, 2022
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
April 13, 2022
From Glaukos Corporation
Via Business Wire
News headline image
Sight Sciences' Q4 Earnings, FY22 Guidance Beat Street View ↗
March 25, 2022
Sight Sciences Inc (NASDAQ: SGHT) has treated the first patient in the TRIDENT trial evaluating OMNI Surgical System compared to Glaukos Corp's (NYSE... 
Via Benzinga
News headline image
Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy
March 14, 2022
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
February 22, 2022
From Glaukos Corporation
Via Business Wire
News headline image
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
News headline image
Glaukos Announces Executive Leadership Changes
February 07, 2022
From Glaukos Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022 ↗
February 03, 2022
Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago... 
Via Benzinga
News headline image
Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22
February 01, 2022
From Glaukos Corporation
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022 ↗
January 19, 2022
Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo... 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
January 12, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award ↗
January 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen... 
Via Benzinga
News headline image
Glaukos' iDose TR Shows Sustained Reduction In Ocular Pressure, Favorable Safety Profile ↗
January 12, 2022
Ophthalmic medical company Glaukos Corporation (NYSE: GKOS) announced data from the Phase 2b trial of iDose TR, a sustained-release travoprost implant. The... 
Via Benzinga
News headline image
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia
January 11, 2022
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
January 11, 2022
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study
January 11, 2022
From Glaukos Corporation
Via Business Wire
News headline image
The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs ↗
January 07, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap